drugset / Trial / NCT05166096

Comparative Pharmacokinetic, Pharmacodynamic, and Safety Study of 1 Dose Level of Aspirin for Injection and Oral Aspirin Tablets in Healthy Adult Human Subjects

NCT05166096

Phase 1 Completed 24 enrolled Rhoshan Pharmaceuticals Inc
RandomizedCrossoverOpen-labelBasic science

Summary

The purpose of this study is to compare the safety, pharmacokinetics, and pharmacodynamic effects of aspirin administered intravenously with aspirin administered orally.

Timeline

Start
2021-12-03
Primary completion
2022-05-11
Completion
2022-05-11

Drugs

EvaluationDrugModalityDoseRoute
Subject Aspirin Small molecule 325 mg Intravenous

Indications

No indication recorded.